Administration of growth factors for the treatment of CNS disorders

Patent metadata

Field	Value
Publication number	US-9724387-B2
Application number	US-201514707868-A
Country	US
Kind code	B2
Filing date	May 8, 2015
Priority date	Apr 25, 2006
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.

First claim

What is claimed is:

1. A method of treating a human patient for Huntington's disease, comprising:
administering to a target brain tissue of said patient a therapeutically effective amount of a pharmaceutical composition comprising a growth factor that promotes the survival of neurons in the target tissue;
wherein said growth factor is administered by intermittent convection enhanced delivery (CED) at a rate that counters the tissue clearance rate of said growth factor, wherein there is cessation of growth factor delivery during the intermissions between administrations, wherein the intermissions between administrations of said growth factor are at least about one week;
wherein said Huntington's disease is treated.

2. The method according to claim 1 , wherein said pharmaceutical composition further comprises a tracing agent.

3. The method according to claim 1 , wherein said CED comprises incremental increases in flow rate.

4. The method according to claim 1 , wherein the pharmaceutical composition is delivered with the use of a CED-compatible reflux-free step-design cannula.

5. The method according to claim 2 , wherein the tracing agent comprises an MRI magnet or a CT-detectable agent.

6. The method according to claim 2 , wherein said tracing agent comprises a liposome.

7. The method according to claim 2 , wherein said tracing agent is a gadolinium chelate.

8. The method according to claim 1 , wherein said pharmaceutical composition comprises a high molecular weight neurotherapeutic comprising said growth factor.

9. The method according to claim 1 , wherein said pharmaceutical composition further comprises low molecular weight heparin as a facilitating agent.

10. The method according to claim 1 , wherein said growth factor is selected from: NGF, BDNF, GDNF, CNTF, IGF-1, b-FGF, neurturin, and VEGF.

11. The method according to claim 1 , wherein the intermissions between administrations of said growth factor are between about 7 and 45 days.

12. The method according to claim 1 , wherein the intermissions between administrations of said growth factor are between about 14 and 45 days.

13. The method according to claim 1 , wherein the intermissions between administrations of said growth factor are between about 17 and 35 days.

14. The method according to claim 1 , wherein the intermissions between administrations of said growth factor are between about 20 and 35 days.

15. The method according to claim 2 , further comprising monitoring said tracing agent to determine distribution of infusate, wherein cessation of delivery occurs when infusate is distributed throughout the substantial whole of the target brain tissue.

16. The method according to claim 2 , further comprising monitoring said tracing agent to determine distribution of infusate, wherein cessation of delivery occurs while infusate remains substantially confined to the target brain tissue.

17. The method according to claim 1 , comprising three or more administrations, wherein the durations of two or more intermissions are varied in length of time.

18. The method according to claim 1 , wherein the duration of intermissions increases over time.

Assignees

• Univ California

Inventors

• Bankiewicz Krystof S

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title